CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

XPro1595Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug92 BCG Vaccine Wiki 0.58

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.11
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Phase 2 Randomised Trial Using XPro1595 to Treat Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)

The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.

NCT04370236 COVID-19 Drug: XPro1595

Primary Outcomes

Description: Treatment failure is defined by progression to one of the following: Transfer to ICU Need for mechanical New onset myocardial infarction or congestive heart failure Requirement for renal replacement therapy New onset of neurologic symptoms New onset of thrombotic or embolic event Death

Measure: Proportion of participants with treatment failure

Time: 28 days

Secondary Outcomes

Measure: Proportion of participants with an increase in the World Health Organization (WHO) Ordinal Scale of Clinical Improvement

Time: 28 days

Measure: Time to treatment failure

Time: 28 days

Measure: Proportion of patients with all-cause mortality

Time: 28 days

Measure: Time to death

Time: 28 days

Measure: Length of index-hospital stay

Time: 28 days

Measure: Length of ICU level of care

Time: 28 days

Other Outcomes

Measure: Number of Days with Fever

Time: 28 days

Measure: Readmission before day 28 for any reason due to COVID-19

Time: 28 days

No related HPO nodes (Using clinical trials)